Saniona AB (publ) (STO:SANION)

Market Cap	2.18B
Revenue (ttm)	339.70M
Net Income (ttm)	214.40M
Shares Out	138.03M
EPS (ttm)	1.82
PE Ratio	8.66
Forward PE	7.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	846,237
Average Volume	1,109,797
Open	14.82
Previous Close	14.80
Day's Range	14.82 - 15.96
52-Week Range	2.51 - 16.36
Beta	1.09
RSI	67.57
Earnings Date	Nov 27, 2025

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SANION